Ultragenyx Raises $14M in Seed Round: Breaking Barriers in Rare Disease Therapies

Amlogenyx is excited to announce that it has successfully raised $14 million in its latest funding round, solidifying its position as a pioneering leader in the development of innovative therapies for rare and ultrarare diseases. With a steadfast commitment to improving the lives of individuals and families battling debilitating genetic conditions, Amlogenyx aims to accelerate the advancement of its groundbreaking clinical pipeline, which encompasses a diverse array of novel treatments that currently lack approved options. Founded in 2010, the company has quickly risen to prominence by prioritizing patient care, fostering an inclusive work environment, and tapping into the extraordinary talent of its dedicated team members who are passionate about making meaningful impacts in the rare disease community. The funds raised will be strategically invested in furthering Amlogenyx's research initiatives and expanding its portfolio of transformative therapies, addressing the high unmet medical needs faced by patients. Amlogenyx believes that every effort counts in the quest to unlock more possibilities for those with rare diseases, and this funding marks a significant milestone in their journey toward delivering hope and healing. As stated by CEO Emil D. Kakkis, M.D., Ph.D., "At Amlogenyx, we are positioning ourselves to deliver on the promise of innovative therapies, and with the support of our investors, we're confident in our ability to change lives." Join us as we continue to lead with purpose every day, embracing professions that encourage curiosity, collaboration, and a shared commitment to transforming the landscape of rare disease treatment.